Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?
Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 3 therapeutic monoclonal antibodies (MAbs).
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.
Integral Molecular Enables Membrane Protein Antibody Discovery
INDUSTRY EXPERIENCE
With 15+ years experience, Integral Molecular is the industry leader in isolating and characterizing complex membrane proteins.Proven Quality
Integral Molecular’s technologies have contributed to scientific discoveries featured in 200+ peer-reviewed publications.Open Communication
Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.Membrane Protein Solutions
MPS Antibody Discovery
Our full suite of Membrane Protein Solutions delivers diverse panels of functional MAbs
Lipoparticles
Our virus-like particles contain high levels of native membrane proteins for better immunization and screening
Epitope Mapping
Our Ala-scan epitope mapping service provides mechanism of action data and strengthens IP
Membrane Proteome Array
We screen antibodies against 6,000 human membrane proteins for deorphaning and de-risking studies
Vaccine Development
We provide innovative tools, including Reporter Virus Technology, for rapid immunocharacterization
Therapeutic Pipeline
We offer licensing opportunities for therapeutic antibodies against untapped targets200+ Publications Including Cell, Science & Nature
Trusted by 300+ Companies
Ready to Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let's talk about how we can help you.
Or call (215) 966-6061